Life Science News

Salix Announces 2023 Gastrointestinal Health Scholars Program

Salix to Provide Scholarships to 10 Students Living with GI Diseases

Bausch Health Companies Inc. (NYSETSX:BHC) today announced the opening of the 2023 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals

"At Salix, we are honored to grant scholarships to commendable students living with GI disease to aid them in the pursuit of their higher education goals. Now in its fourth year, Salix is committed to advancing the Salix Gastrointestinal Health Scholars Program, as we look toward providing more students with the support they need," said Nicola Kayel, vice president, GI Marketing, Salix.

Students can apply for this scholarship by completing the online application, submitting letters of reference, and writing an essay on the impact having a diagnosed GI condition has had on their life and the role that a health care provider played in helping to manage their condition. Scholarships are offered to school applicants or current attendees of a two- or four-year college, university, or an advanced (post-high school) vocational or technical school for the 2023-2024 academic year and are available in four categories:

  • Undergraduate Scholar Awards for students pursuing undergraduate degrees
  • Graduate Scholar Awards for students pursuing graduate degrees
  • Working Parent's Scholar Award for students who are parents pursuing undergraduate, vocational/technical or graduate degrees
  • Single Parent's Scholar Award for students who are single parents pursuing undergraduate, vocational/technical or graduate degrees

The application period for the Salix Gastrointestinal Health Scholars Program will close on May 15, 2023, and scholarship recipients will be notified in the summer of 2023. To learn more about the scholarship, including eligibility criteria, terms and conditions, please visit www.salix.com/scholarship.

About Salix

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Investor Contact:

ir@bauschhealth.com
(877) 281-6642 (toll-free)

Media Contact:

Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785

Gianna Scalera
salixcommunications@bauschhealth.com
(908) 541-2110

SOURCE: Bausch Health Companies Inc.



View source version on accesswire.com:
https://www.accesswire.com/738992/Salix-Announces-2023-Gastrointestinal-Health-Scholars-Program

News Provided by ACCESSWIRE via QuoteMedia

BHC:CA,BHC
The Conversation (0)

InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has promoted Andrea Tommasoli to Chief Operating Officer. Mr. Tommasoli formerly served as the Company's Senior Vice President of Global Sales & Marketing since joining InspireMD in November 2020.

"Andrea has been instrumental in expanding the footprint of CGuard EPS across our approved markets in the EU and, as we advance toward potential U.S. approval with our ongoing U.S. Investigational Device Exemption (IDE) clinical trial, and as our business requirements shift toward operational capacity to support our commercial growth, we believe his background and skill set make him an ideal candidate to assume the role of Chief Operating Officer of the Company at this important time," stated Marvin Slosman, Chief Executive Officer of InspireMD. "On behalf of the entire InspireMD team, I would like to congratulate Andrea on this promotion and look forward to his continued contributions."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman

Gemini BioProducts Holding, Inc. ("GeminiBio" or the "Company"), a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida -based healthcare private equity firm, announced the appointment of Cory Stevenson as Executive Chairman of the Board of Directors.

(PRNewsfoto/BelHealth Investment Partners)

Mr. Stevenson joined the Board of GeminiBio in 2022 and has been working closely with the GeminiBio management team as they prepare to complete a three-phase buildout that addresses the long-term capacity needs in the biopharma and cell/gene therapy marketplace. Previously, Mr. Stevenson served as President of the BioProduction Division of Thermo Fisher Scientific (NYSE:TMO), a world leader in serving the biopharma sector, with annual revenue of more than $40 billion . During Cory's tenure, the BioProduction business grew from $200 million in revenues to over $2.5 billion annually.

Harold S. Blue , Managing Partner of BelHealth Investment Partners said, "We are fortunate to have Cory expand his role and guide our strategy at GeminiBio. Cory has been very helpful during the last year as a board member and I am excited that he will be taking a more active role. Also, given that Cory worked directly with GeminiBio's CEO, Brian Parker , while at Thermo Fisher, this was a natural fit."

Cory Stevenson , Executive Chairman of GeminiBio added, "I am delighted to expand my role at GeminiBio after working closely with Brian and the rest of the team since I joined the Board. With the completion of its 57,000-square-foot manufacturing facilities, GeminiBio is positioning itself as a vendor delivering much-needed critical solutions to the global biopharma industry. I am looking forward to this exciting next phase at GeminiBio."

About BelHealth Investment Partners

BelHealth Investment Partners, based in Fort Lauderdale, Florida , is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management, and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes will benefit from its extensive operating and private equity investment expertise. For more information, visit www.belhealth.com .

About GeminiBio

Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping our customers accelerate the development of life enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows. The company's products are organized into two core verticals – Cell Culture Solutions and Process Liquid Solutions. Located in West Sacramento, California , GeminiBio has 57,000 square feet of cGMP manufacturing space that is segregated between animal origin free and animal component manufacturing. GeminiBio is an ISO 13485 certified, FDA registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820. For more information, visit www.geminibio.com .

Contact:
BelHealth: Inder Tallur , itallur@belhealth.com
GeminiBio: bparker@geminibio.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/geminibio-appoints-industry-veteran-cory-stevenson-as-executive-chairman-301774586.html

SOURCE BelHealth Investment Partners

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2022 financial results on Thursday, March 23, 2023 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 23, 2023

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature

The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans

Findings support further clinical development for prevention and treatment of dengue, which impacts millions of people today and is poised to threaten many more due to climate change

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Medtronic receives CE Mark approval for Affera Mapping and Ablation System to treat atrial arrhythmias

First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform

Medtronic (NYSE:MDT) announced today that it has received CE ( Conformité Européenne ) Mark for the Affera™ Mapping and Ablation System, which includes the Sphere-9™ Catheter and the Affera™ Prism-1 Mapping Software. Together, the full system creates a new paradigm in electrophysiology through the unique integration of the Sphere-9 pulsed field ablation (PFA), radiofrequency (RF), and high density (HD) mapping catheter, which maps and ablates atrial arrhythmias (fast, abnormal heart rhythms) and provides real-time feedback through its intuitive mapping and navigation software. Atrial fibrillation (AFib) is the most common atrial arrhythmia, and nearly 60 million people are affected worldwide 1 and five million patients will be added every year by 2030 2 . Atrial arrhythmias, such as AFib, are associated with serious complications including heart failure, stroke and increased risk of death 3-6 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic named one of World's Most Ethical Companies

Recognition honors companies demonstrating business integrity through best-in-class ethics, compliance, and governance practices

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has been recognized by Ethisphere, a leader in defining and advancing the standards of ethical business practices, as one of the 2023 World's Most Ethical Companies . In 2023, 135 honorees were recognized spanning 19 countries and 46 industries. Medtronic is one of only two honorees in the 'Healthcare Products' industry category.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×